Agios Pharmaceuticals. Every tracked FinTwit mention of $AGIO, newest first. 11 mentions since the first on Sep 4, 2025. See the price chart.
April 2026 · 2 mentions
Apr 20
Adam Feuerstein ✡️ — $AGIO -16% on $NVO study outcome in sickle cell disease.↗
Apr 8
Nancy Pelosi Stock Tracker ♟ — New: Gil Cisneros (D) just filed up to $1,300,000 of new stock trades
The ones that stood out are 3 pharma picks: $AGIO, $BBIO, and $RARE
The crazy part is that all 3 had major F…↗
December 2025 · 1 mention
Dec 8
Adam Feuerstein ✡️ — $AGIO FDA decision on mitapvat thalassemia submission delayed
https://t.co/AP586ykG0I↗
November 2025 · 7 mentions
Nov 19
Adam Feuerstein ✡️ — @MelvinRiskMgmt @sciencescanner $AGIO stock would still be down but chances for approval better had the study hit on fatigue. It did not, which is a big problem.↗
Nov 19
Adam Feuerstein ✡️ — Agios $AGIO reports mixed results from sickle cell study, raising doubts about drug’s future https://t.co/WbuQ34e2mh↗
Nov 19
Adam Feuerstein ✡️ — An unfortunate outcome given the need for new sickle cell treatments following the withdrawal of Pfizer's Oxbryta.
I wrote a preview of the $AGIO study last week:
https://t.co/…↗
Nov 19
Adam Feuerstein ✡️ — @sciencescanner The $AGIO stock reaction to the results are indicative that Hb alone is insufficient to support an approval.
September 2025 · 1 mention
Sep 4
Adam Feuerstein ✡️ — $AGIO Pyrukynd PDUFA for thalassemia extended by 3 months to Dec. 7.
Liver toxicity issue.
"Following a recent information request from the FDA, Agios submitted a proposed Risk…↗
Adam Feuerstein ✡️ — $AGIO mitapivat ph3 sickle cell trial results results, not great.
Hit stat sig hemoglobin response, failed on pain crises
Fatigue, key secondary, also not met.
https://t.co/Bo…↗
Nov 13
Adam Feuerstein ✡️ — A preview of Agios Pharma’s $AGIO sickle-cell study readout
https://t.co/d4HOAOYvSS↗
Nov 13
Adam Feuerstein ✡️ — In this week's Biotech Scorecard:
-- $QURE CEO Matt Kapusta dined privately with investors on Tuesday night -- and said some stuff, according to two attendees who filled me in.
-…↗